Skip to main content

Table 1 Patients’ characteristics

From: Androgen receptor mRNA expression is a predictor for recurrence-free survival in non-muscle invasive bladder cancer

Age, median (range)

74.1 (40.5–88.8)

Sex, n (%)

 Male

48 (90.6%)

 Female

5 (9.4%)

Primary or recurrence, n (%)

 Primary

42 (79.2%)

 Recurrence

11 (20.8%)

Recurrence within one year, n (%)

 Yes

9 (17.0%)

 No

44 (83.0%)

Tumor grade, n (%)

 Low

39 (73.6%)

 High

14 (26.4%)

T stage, n (%)

 pTa

42 (79.2%)

 pT1

11 (20.8%)

Number of tumor, n (%)

 Single

24 (45.3%)

 Multiple

29 (54.7%)

Tumor size, n (%)

  < 3 cm

46 (86.8%)

  ≥ 3 cm

7 (13.2%)

Concurrent CIS, n (%)

 Yes

2 (3.8%)

 No

51 (96.2%)

Immediate intravesical chemotherapy, n(%)

 Yes

51 (96.2%)

 No

2 (3.8%)

Additional adjuvant intravesical chemotherapy, n (%)

 Yes

12 (22.6%)

 No

41 (77.4%)

Second TUR, n (%)

 Yes

6 (11.5%)

 No

47 (88.5%)

  1. CIS carcinoma in situ, TUR transurethral resection